|
PPAR gamma activation Impact on pathways of clinical care
|
|
|
New paradigm of multiple risk factormanagement
|
|
|
TRIPOD:
|
|
|
TRIPOD & PIPOD:
|
|
|
Anticipated results from large multicenter trials in (pre)diabetes
|
|
|
DREAMBackground and study objective
|
|
|
DREAMStudy design
|
|
|
DREAM:
|
|
|
DREAM results: Summary
|
|
|
TZDs blunt diabetes progression
|
|
|
Anticipated results from large multicenter trials in (pre)diabetes
|
|
|
CHICAGO: Background and rationale
|
|
|
CHICAGO: Study design
|
|
|
CHICAGO: Baseline risk factors
|
|
|
CHICAGO: Treatment effect on glucose control
|
|
|
CHICAGO: Treatment effect on posterior wall mean CIMT
|
|
|
CHICAGO: Treatment effect on posterior wall mean CIMT
|
|
|
CHICAGO: Summary
|
|
|
CHICAGO: Implications
|
|
|
CHICAGO: Implications
|
|
|
Aggressive medical therapy in diabetes
|
|
|
Summary: Optimizing outcomes in patients with multiple CVD risks
|
|
Share this page with your colleagues and friends: